U.S. Markets closed

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
115.05+0.18 (+0.16%)
At close: 4:00PM EDT

115.05 0.00 (0.00%)
After hours: 4:23PM EDT

People also watch
VRTXBMRNALXNREGNSGEN
Full screen
Previous Close114.87
Open114.53
Bid112.99 x 100
Ask115.00 x 2400
Day's Range112.81 - 116.24
52 Week Range83.01 - 153.15
Volume1,580,284
Avg. Volume1,354,928
Market Cap24.24B
Beta1.63
PE Ratio (TTM)-145.27
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markityesterday

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $456 million.

  • Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
    Zacks6 days ago

    Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

    Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

  • Reuters7 days ago

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.